» Articles » PMID: 34459722

Benefits of Multi-day Supplementation with Probiotic Kefir in Rasmussen Encephalitis: the First Case Report

Overview
Journal Nutr Neurosci
Date 2021 Aug 30
PMID 34459722
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Rasmussen encephalitis (RE) is a rare inflammatory disease, characterized by unilateral hemispheric atrophy, focal intractable seizures, progressive hemiparesis, and neurological deficits.

Case Report: The patient is a young man under pharmacotherapy for epilepsy, exhibiting classical abnormal movements, which are consider typical hallmarks of RE. During clinical care sessions, he presented many episodes of tonic-clonic seizures involving sudden loss of consciousness followed by a post-ictal phase with weakness and interaction difficulty. During the kefir supplementation, the patient presented only short-term absence seizures, quickly returning to activities. Additionally, he presented cognitive and language improvement, being more responsive to commands. The daily diary control of patient's mother and caregiver at school reported an impressive reduction in number and severity of seizures, becoming less aggressive and more involved in school activities. The serum biochemical markers showed that kefir administration caused a significant decrease of pro-inflammatory and a simultaneous increase of anti-inflammatory cytokine levels. In parallel, after treatment, this probiotic reduced reactive oxygen species levels, increased NO bioavailability, revealing antiapoptotic and antigenotoxic effects. Regarding the microbiological analysis, kefir increased Lactobacillus and Bifidobacterium species.

Conclusion: To our knowledge, this is the first case reporting remarkable beneficial effects of the probiotic kefir in RE. This case report strongly suggests kefir supplementation as a potential and safe-effective adjuvant therapeutic strategy in the control and treatment of RE.

Citing Articles

Efficacy of probiotic adjuvant therapy in women with major depressive disorder: insights from a case series study.

Junior J, Aires R, de Sousa Cutrim T, Vasquez E, Pereira T, Campagnaro B Pharmacol Rep. 2025; .

PMID: 39808404 DOI: 10.1007/s43440-024-00690-6.


The interplay between microbiota and brain-gut axis in epilepsy treatment.

Zhu H, Wang W, Li Y Front Pharmacol. 2024; 15:1276551.

PMID: 38344171 PMC: 10853364. DOI: 10.3389/fphar.2024.1276551.


Unravelling the Gastroprotective Potential of Kefir: Exploring Antioxidant Effects in Preventing Gastric Ulcers.

Coco L, Aires R, Carvalho G, Belisario E, Yap M, Amorim F Cells. 2023; 12(24).

PMID: 38132119 PMC: 10742242. DOI: 10.3390/cells12242799.


Role of Short Chain Fatty Acids in Epilepsy and Potential Benefits of Probiotics and Prebiotics: Targeting "Health" of Epileptic Patients.

Kim S, Park S, Choi T, Kim S Nutrients. 2022; 14(14).

PMID: 35889939 PMC: 9322917. DOI: 10.3390/nu14142982.


The Emerging Scenario of the Gut-Brain Axis: The Therapeutic Actions of the New Actor Kefir against Neurodegenerative Diseases.

Pereira T, Coco L, Ton A, Meyrelles S, Campos-Toimil M, Campagnaro B Antioxidants (Basel). 2021; 10(11).

PMID: 34829716 PMC: 8614795. DOI: 10.3390/antiox10111845.